Amneal Pharmaceuticals
AMRX
175 hedge funds and large institutions have $651M invested in Amneal Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 67 increasing their positions, 47 reducing their positions, and 7 closing their positions.
800% more call options, than puts
Call options by funds: $4.53M | Put options by funds: $503K
343% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 47
14% more funds holding
Funds holding: 153 → 175 (+22)
2.03% less ownership
Funds ownership: 36.86% → 34.83% (-2%)
5% less capital invested
Capital invested by funds: $686M → $651M (-$34.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$8.7M |
| 2 |
BCP
BlackBarn Capital Partners
New York
|
+$7.97M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.62M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$3.88M |
| 5 |
Morgan Stanley
New York
|
+$2.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
-$51.9M |
| 2 |
Neuberger Berman Group
New York
|
-$20.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.06M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$2.65M |
| 5 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$2.51M |
AMRX Hedge Fund Activity: Q1 2024 in Review
175 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q1 2024, worth a combined $651M — down 5.1% from $686M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new AMRX positions and 7 closed out — a net gain of 24 holders — while 67 added to existing stakes and 47 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $8.7M. The largest seller was Fosun International, cutting an estimated $51.9M.
- 175 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q1 2024, up from 153 in Q4 2023.
- Funds reported $651M of Amneal Pharmaceuticals stock for Q1 2024, down 5.1% quarter-over-quarter.
- 31 funds opened new Amneal Pharmaceuticals positions in Q1 2024 and 7 closed out, a net change of +24 holders.
- The largest Amneal Pharmaceuticals buyer in Q1 2024 was Rubric Capital Management (New York), an estimated $8.7M added.
- The largest Amneal Pharmaceuticals seller in Q1 2024 was Fosun International, an estimated $51.9M sold.
Based on aggregated 13F filings for Q1 2024.